← Leaderboards
Michael John Evans
University Of California, San Francisco
$10,372,266
Attributed
$18,554,227
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,554,227 · 10
By mechanism
R01$17,735,139 · 8
R00$728,269 · 1
K99$90,819 · 1
Top collaborators
- Charles Scott Craik11 shared
- Jason S Lewis9 shared
- Rahul Aggarwal8 shared
- Lawrence Fong4 shared
- Adam R Renslo4 shared
- David M Wilson4 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Rahul Aggarwal$5,953,056
- Thomas Hope$3,566,163
- Charles Scott Craik$31,131,909
- Ajay V. Maker$3,064,358
- Felix Yi-Chung Feng$6,764,664
Research focus
Positron-Emission TomographyImageRadiotracerResponseTumorInnovationIn VivoMalignant NeoplasmsTechnologyUptakeDrug KineticsPre-ClinicalSignal TransductionBiologyBaseLabelDetectionPharmaceutical PreparationsIn VitroProteinsBiological MarkersTranslationsCommunitiesPharmacology
Grant awards (36)
Maximizing tumor responses to targeted radiotherapy with a conditionally activated membrane binding probe$669,794
R01 · FY2025 · CA · contact PI
Precision targeting of T cell cytotoxicity with PET$643,445
R01 · FY2025 · CA · contact PI
New radiotracer development to study immune cell mobilization of granzyme proteolytic activity$743,029
R01 · FY2024 · AI · contact PI
Maximizing tumor responses to targeted radiotherapy with a conditionally activated membrane binding probe$616,174
R01 · FY2024 · CA · contact PI
Precision targeting of T cell cytotoxicity with PET$611,272
R01 · FY2024 · CA · contact PI
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications$598,029
R01 · FY2024 · EB · contact PI
Combining immunotherapy with molecularly targeted radiation therapy$663,343
R01 · FY2023 · CA
New radiotracer development to study immune cell mobilization of granzyme proteolytic activity$660,398
R01 · FY2023 · AI · contact PI
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications$642,126
R01 · FY2023 · EB · contact PI
Precision targeting of T cell cytotoxicity with PET$635,683
R01 · FY2023 · CA · contact PI
New radiotracer development to study immune cell mobilization of granzyme proteolytic activity$740,394
R01 · FY2022 · AI · contact PI
Precision targeting of T cell cytotoxicity with PET$652,933
R01 · FY2022 · CA · contact PI
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications$643,387
R01 · FY2022 · EB · contact PI
New radiotracer development to study immune cell mobilization of granzyme proteolytic activity$676,766
R01 · FY2021 · AI · contact PI
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications$675,144
R01 · FY2021 · EB · contact PI
Development of a translational imaging tool as a predictive biomarker for anti-PD-1/PD-L1 immunotherapies$557,470
R01 · FY2021 · EB · contact PI
Precision targeting of T cell cytotoxicity with PET$524,205
R01 · FY2021 · CA · contact PI
Development and translation of a novel radioligand to measure pathological changes in glucocorticoid receptor expression in the brain$633,938
R01 · FY2020 · MH · contact PI
Development of a translational imaging tool as a predictive biomarker for anti-PD-1/PD-L1 immunotherapies$591,330
R01 · FY2020 · EB · contact PI
Development and translation of a novel radioligand to measure pathological changes in glucocorticoid receptor expression in the brain$667,719
R01 · FY2019 · MH · contact PI
Development of a translational imaging tool as a predictive biomarker for anti-PD-1/PD-L1 immunotherapies$586,828
R01 · FY2019 · EB · contact PI
Development and translation of a novel radioligand to measure pathological changes in glucocorticoid receptor expression in the brain$690,814
R01 · FY2018 · MH · contact PI
Development of a translational imaging tool as a predictive biomarker for anti-PD-1/PD-L1 immunotherapies$557,734
R01 · FY2018 · EB · contact PI
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$563,930
R01 · FY2017 · CA
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$15,013
R01 · FY2017 · CA
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$631,257
R01 · FY2016 · CA
Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin$241,072
R00 · FY2016 · CA · contact PI
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$67,007
R01 · FY2016 · CA
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$566,741
R01 · FY2015 · CA
Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin$245,941
R00 · FY2015 · CA · contact PI
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$67,007
R01 · FY2015 · CA
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$541,423
R01 · FY2014 · CA
Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin$241,256
R00 · FY2014 · CA · contact PI
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$51,996
R01 · FY2014 · CA
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$548,810
R01 · FY2013 · CA
Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin$90,819
K99 · FY2013 · CA · contact PI